Influencia de la anhedonia en la evolución clínica del trastorno depresivo

  1. M.E. Presa García 1
  2. A. García Luque 2
  3. L. Luis Callol Sánchez 3
  4. A. Abril García 4
  5. M.A. Muñoz-Lucas 5
  1. 1 Teniente coronel médico psiquiatra. Jefe del Servicio de Psiquiatría y Salud Mental. Hospital Central de la Defensa.
  2. 2 Teniente coronel médico. Jefe del Servicio de Farmacología Clínica. Hospital Central de la Defensa.
  3. 3 Profesor emérito de medicina UCM.
  4. 4 Médico psiquiatra. Jefe de Consultas Externas del Servicio de Psiquiatría y Salud Mental. Hospital Central de la Defensa.
  5. 5 Ayuda a la investigación. Jefatura de Docencia e Investigación. Hospital Central de la Defensa.
Revista:
Sanidad militar: revista de sanidad de las Fuerzas Armadas de España

ISSN: 1887-8571

Any de publicació: 2023

Volum: 79

Número: 2

Pàgines: 75-81

Tipus: Article

Altres publicacions en: Sanidad militar: revista de sanidad de las Fuerzas Armadas de España

Resum

Anhedonia is the absence or reduced ability to experience pleasure. It is a major symptom of depression and a negative symptom of schizophrenia. We present a prospective descriptive study (December 2018 to July 2020) with a 6-month follow-up, developed in the Psychiatric Outpatient Clinic of the “Hospital Central de la Defensa, Gómez Ulla”. The SHAPS scale was used to quantify anhedonia and the CET-DE questionnaire was used to monitor clinical depression. Other scales such as the CGI scale (subjective impression of severity/improvement was use by the psychiatrist) and the modified VAS (patient’s subjective impression of his or her state of severity) were also applied. Out of 60 patients recruited, 48 completed the study protocol (2 visits), 60 % were women with a mean age of 48 years. At the firts visit the percentage of anhedonia was 67 %, with 48 % considered severe by the physician. The presence of anhedonia was related to a higher score on the CET-DE scale. After the psychotherapeutic intervention, the percentage of anhedonia at the last visit was 29% in general and 25% of patients were classified as severe by the health professional. The persistence of anhedonia at the final visit was a factor of poor clinical evolution and we can conclude that it is a component of the residual symptomatology of depression and an indicator of poor prog

Referències bibliogràfiques

  • 1. Asociación Americana de Psiquiatría. (2014). Manual Diagnóstico y Estadístico de Trastornos Mentales (DSM-5®). 5.ª ed. Arlington, Asociación Americana de Psiquiatría.
  • 2. Romer Thomsen, K., Whybrow, P. y Kringelbach, M. (2015). Reconceptualizing anhedonia: novel perspectives on balancing the pleasure networks in the human brain [en línea]. Front Behav Neurosci. 11 (9), pp. 49. Disponible en: https://www.frontiersin.org/articles/10.3389/fnbeh.2015.00049/full
  • 3. Der-Avakian A, Markou A. (2012). The neurobiology of anhedonia and other reward-related deficits [en línea]. Trends in Neurosciences. 35 (1), pp. 68–77. Disponible en: https://pubmed.ncbi.nlm.nih.gov/22177980/
  • 4. Rizvi, S. J., Lambert, C. y Kennedy, S. (2018). Presentation and Neurobiology of Anhedonia in Mood Disorders: Commonalities and Distinctions. Current Psychiatry Reports. 20 (2), pp. 13. Disponible en: https://europepmc.org/article/med/29520717
  • 5. Millón, C. et al. (2019). Role of the galanin N-terminal fragment (1-15) in anhedonia: Involvent of the dopaminergic mesolimbic system. Journal of Psychopharmacology. 33 (6), pp. 737-804. Disponible en: https://journals.sagepub.com/doi/10.1177/0269881119844188
  • 6. Genders, S. G., Scheller, K. J. y Djouma, E. (2018). Neuropeptide modulation of addiction: Focus on galanin. Neurosci Biobehav Rev 110, pp. 133-148. DOI: 10.1016/j.neubiorev.2018.06.021
  • 7. Gold, M. S., Blum, K. y Febo, M. (2018). Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti- reward systems. Front Biosci (Schol Ed) 10, pp. 309-325. DOI: 10.2741/s518
  • 8. Russo, S. J. y Nestler, E. J. (2013). The brain reward circuitry in mood disorders. Nature Reviews Neuroscience. 14, pp. 609–625. DOI: https://doi. org/10.1038/nrn3381
  • 9. Rizvi, S. J. et al. (2016). Assessing anhedonia in depression: Potencials and pills. Neurosci Biobehav Rev., pp. 21-35. DOI: 10.1016/j.neubiorev.2016.03.004
  • 10. Snaith R. P. et al. (1995). Scale for the assessment of hedonic tone the SnaithHamilton Pleasure Scale. Br J Psychiatry. 167, pp. 99-103. DOI: 10.1192/ bjp.167.1.99
  • 11. Alonso-Fernández, F. (1986). CET-DE Cuestionario Estructural Tetradimensional para la Depresión. Manual. Madrid, TEA. Disponible en: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://web.teaediciones. com/Ejemplos/CET-DE%20_extracto%20web.pdf
  • 12. Guy W. (1976). Early Clinical Drug Evaluation (ECDEU). Assessment Manual. Rockville (eds.). National Institute Mental Health.
  • 13. Fresán A. y Berlanga C. (2013). Traducción al español y validación de la escala de Placer Snaith-Hamilton para anhedonia (Shaps). Actas Esp Psiquiatr. 41 (4), pp. 227-231.
  • 14. Vicente Herrero, M. T. et al. (2018). Valoración del dolor. Revisión comparativa de escalas y cuestionarios. Revista de la Sociedad Española del dolor 25 (4), pp. 228-236. Disponible en: https://scielo.isciii.es/scielo.php?pid=S1134- 80462018000400228&script=sci_arttext
  • 15. Ministerio de Sanidad Consumo y Bienestar Social. (2017). Encuesta Nacional de Salud. España. Disponible en: https://www.sanidad.gob.es/ estadEstudios/estadisticas/encuestaNacional/encuesta2017.htm
  • 16. Olivares, J. M. (2007). Psicopatología de los estados de ánimo: Anhedonia. Informaciones Psiquiátricas. Disponible en: www.informacionespsiquiatricas. com/anteriores/info_2007/03_189_06.htm
  • 17. Demyttenaere, K. et al. (2015). What is important in being cured from depression? Discordance between physicians and patients. J Affect Disorders. 174, pp. 390-406. DOI: 10.1016/j.jad.2014.12.004.
  • 18. Martinotti, G., Cloninger, C. R., y Janiri, L. (2008). Temperament and character inventory dimensions and anhedonia in detoxified substance-dependent subjects. The American Journal of Drug and Alcohol Abuse. 34 (2), pp.177-183. DOI: 10.1080/00952990701877078
  • 19. Pelizza, L. y Ferrari, A. (2009). Anhedonia in schizophrenia and major depression: state or trait? Ann Gen Psychiatry 8, pp. 22. DOI: 10.1186/1744-859X-8-22
  • 20. Zimmermman, M. et al. (2006). How Should Remission From Depression Be Defined? The Depressed Patient’s Perspective. American Journal of Psychiatry 163, pp.148-150. DOI: 10.1176/appi.ajp.163.1.148
  • 21. Trostheim, M. et al. (2020). Assessment of Anhedonia in Adults with and Without Mental Illness: A Systematic Review and Meta-analysis. JAMA Netw Open. 3 (8), pp. e2013233. DOI:10.1001/jamanetworkopen.2020.13233
  • 22. Cao, B. et al. (2019). Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 92 (8), pp. 109-111. DOI: 10.1016/j. pnpbp.2019.01.002.
  • 23. De Fruyt, J., Sabbeb, B. y DemyLenaered, K. (2020). Anhedonia in Depressive Disorder: A Narrative Review. Psychopathology. 53, pp. 274–281. DOI: 10.1159/000508773
  • 24. Di Giannantonio, M., et al. (2019). Agomelatine Effectiveness, Tolerability, and Impact on Anhedonia in Major Depression: A Pooled Analysis. Journal of Clinical Psychopharmacology. 39 (3), pp. 288-290. DOI: 10.1097/ JCP.0000000000001038
  • 25. Ducasse, D. et al. (2018). Anhedonia is associated with suicidal ideation independently of depression: A meta-analysis. Depress Anxiety. 35 (5), pp. 382- 392. DOI: 10.1002/da.22709
  • 26. Bonanni, L. et al. (2019). Can Anhedonia Be Considered a Suicide Risk Factor? A Review of the Literature. Medicina (Kaunas) 55 (8), pp. 458. DOI: 10.3390/medicina55080458.
  • 27. Heerlein, K. et al. (2021). Real-world evidence from a European cohort study of patients with treatment resistant depression: Treatment paLerns and clinical outcomes. Journal of Affective Disorders 290, pp. 334-404. DOI: 10.1016/j. jad.2021.03.073